Boston, MANCT06781983Now EnrollingIRB Ready

Advanced or Metastatic Solid Tumors Clinical Trial in Boston, MA

Access cutting-edge advanced or metastatic solid tumors treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Innate Pharma

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access advanced or metastatic solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced or metastatic solid tumors treatment provided free

Apply for This Boston Location

Check if you qualify for this advanced or metastatic solid tumors clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Advanced or Metastatic Solid Tumors Study in Boston

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Sponsor: Innate Pharma

Who Can Participate

Inclusion Criteria

Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.
Measurable disease according to RECIST 1.1.
Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.
Adequate organ function and hematological function. Main

Exclusion Criteria

Known or suspected brain metastases.
Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
Participants with clinically significant comorbidity(s).
History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.
Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.
Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.
Participants with symptomatic heart failure, Acute coronary syndromes
Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.
Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.
Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06781983) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced or Metastatic Solid Tumors Treatment Options in Boston, MA

If you're searching for advanced or metastatic solid tumors treatment options in Boston, MA, this clinical trial (NCT06781983) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced or metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced or metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Boston, MA

See all advanced solid tumors clinical trials recruiting in Boston — not just this study.

Browse Advanced Solid Tumors Trials in Boston →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA